BUY Glenmark Pharmaceuticals — Prakash Gaba, 13 Aug 2026

byPrakash GabaHorizon: NA (inferred Swing (≤2wk))13 Aug 2026via CNBC Awaaz.

Entry₹2,320Inferred

Target₹2,340

Stop loss₹2,300-0.86% risk

Exit₹2,34014 Aug 2026, 10:30 am

Target hit+0.86%0.00%upside left

Follow Prakash Gaba for new calls(28% target hit, 184 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 1 active Swing call on GLENMARK

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 14 Aug 2026

6 supporting4 neutral1 opposing

Supports the BUY call (6)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·12 Aug · 2d ago

Glenmark Pharma Q1 Revenue Beats Estimates, EBITDA Margins Seen Rising

NewsGoogle News·4 Aug · 1w ago

Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price

NewsNdtv-Profit·4 Aug · 1w ago

Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth

NewsCnbc-Tv18·31 Jul · 2w ago

Glenmark Pharma Q1 Results: Profit Rises Exponentially To Rs 483 Crore; Revenue Jumps 23%

NewsNdtv-Profit·31 Jul · 2w ago

Neutral / worth noting (4)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 2d ago

Glenmark Pharma Q1 FY27 Results and Brokerage Outlook

NewsGoogle News·4 Aug · 1w ago

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·31 Jul · 2w ago

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

BSE · Board Meeting·31 Jul · 2w ago

Weighs against the BUY call (1)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 2d ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.